Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2023
Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
Arthritis Rheumatol. 2023 DOI 10.1002/art.42734
This post hoc analysis of the Phase 2 NOBILITY trial determined that obinutuzumab plus standard of care improved the likelihood of long-term preservation of kidney function and improved kidney function with less glucocorticoid use in patients with lupus nephritis.
Keywords:
August 2023
Effect of Belimumab on Kidney-related Outcomes in Patients with Lupus Nephritis: Post Hoc Subgroup Analyses of the Phase 3 BLISS-LN Trial
Nephrol Dial Transplant. 2023;38(12):2733–42 doi: 10.1093/ndt/gfad167 Epub ahead of print.
These data highlight the consistent benefit of belimumab versus placebo, combined with standard therapy, on kidney outcomes in both newly diagnosed and relapsed patients, and regardless of the use of GC pulses at induction.
April 2023
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Changes in Discrete Subsets of Blood Transcriptomic and Cellular Biomarkers
Br J Dermatol. 2023 doi: 10.1093/bjd/ljad089
Prospective single-centre study of anifrolumab in refractory mucocutaneous SLE, indicates rapid efficacy of anifrolumab in discoid lupus erythematosus (DLE) and rituximab-resistant CLE.
Keywords:
March 2022
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
Lancet Rheumatol. Published online February 3, 2022
Across two pivotal phase 3 trials (TULIP-1 and TULIP-2), anifrolumab treatment improved systemic lupus erythematosus (SLE) disease activity across multiple organ domains, compared with placebo.
November 2021
B-cell Depletion With Obinutuzumab for the Treatment of Proliferative Lupus Nephritis: A Randomised, Double-blind, Placebo-controlled Trial
Ann Rheum Dis. 2021. doi:10.1136/annrheumdis-2021-220920
Phase 2 study data support the use of obinutuzumab in proliferative lupus nephritis (LN) being further evaluated in a global Phase 3 study.